Skip to content

Weak Generic Lenalidomide Sales Cut Natco Pharma's First‑Quarter Earnings

By News Analysis India · · 1 min read

Natco Pharma Ltd disclosed its FY 2026‑27 Q1 results on August 14, showing a steep decline in profitability driven by a soft market for its generic version of the cancer therapy lenalidomide. The company’s consolidated net profit fell 57 percent to Rs 206.5 crore from Rs 480.3 crore a year earlier.

The top line registered a 44.7 percent fall, landing at Rs 735.2 crore versus Rs 1,328.9 crore in the corresponding quarter of the previous fiscal year. The revenue contraction was mainly linked to the drop in lenalidomide sales, although domestic formulation revenues rose to Rs 136.4 crore from Rs 107 crore.

EBITDA decreased by 67.4 percent to Rs 186 crore, pulling the EBITDA margin down to 25.3 percent from 43 percent. Operating costs were reduced to Rs 608.8 crore from Rs 818.7 crore, indicating disciplined spending.

The board announced an interim dividend of Rs 1.50 per share and approved a capital raise of up to Rs 2,000 crore via qualified institutional placement and other allowed avenues to support strategic investments.